Sugammadex 2 mg/kg
Sponsors
Merck Sharp & Dohme LLC, University Hospital, Ghent, Poitiers University Hospital
Conditions
AnesthesiaMorbid ObesityMorbidly Obese PatientsNeuromuscular BlockadeReversal of Neuromuscular Blockade
Phase 2
Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients
CompletedNCT01911520
Start: 2011-01-31End: 2012-06-30Updated: 2021-07-13
Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients
CompletedNCT02545595
Start: 2012-05-31Updated: 2016-10-12
Phase 3
Phase 4
Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)
CompletedNCT03346057
Start: 2017-12-20End: 2019-09-04Updated: 2020-10-08
Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)
CompletedNCT03351608
Start: 2018-02-12End: 2020-01-28Updated: 2021-02-05
Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)
CompletedNCT03909165
Start: 2019-07-23End: 2023-09-21Updated: 2025-07-25